Skip to main content
. 2016 Apr 7;11(4):e0152584. doi: 10.1371/journal.pone.0152584

Fig 4. Talazoparib and BKM-120 act additively to inhibit SCLC growth in vitro.

Fig 4

(A) Proliferation assays using clinically achievable doses of talazoparib (6 doses, range 0.1–30 nM) and BKM-120 (3 doses, range 0.1–1 μM) showed an additive interaction in most of the 50 SCLC cell lines tested. Examples show additive responses (H211, DMS-79), and a greater-than-additive response (H1930). (B) Degree (percentage) of inhibition above (green) or below (pink) the predicted additive effect (purple) for each cell line across all clinically achievable doses. (C) Observed proliferation relative to predicted additive effect at individual doses of BKM-120.